Tag Archives: Adults

FDA Approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Print this page KENILWORTH, N.J.–(BUSINESS WIRE) June 5, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Recarbrio™ (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age… Read More »